Invention Grant
- Patent Title: TGIF2-induced reprogramming of hepatic cells to pancreatic progenitor cells and medical uses thereof
-
Application No.: US14800880Application Date: 2015-07-16
-
Publication No.: US10526577B2Publication Date: 2020-01-07
- Inventor: Francesca Spagnoli , Nuria Cerda-Esteban
- Applicant: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN
- Applicant Address: DE Berlin
- Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN
- Current Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN
- Current Assignee Address: DE Berlin
- Agency: Agris & Von Natzmer, LLP
- Agent Joyce Von Natzmer
- Priority: EP14177287 20140716
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C12N5/02 ; C12N5/071 ; A61K35/39 ; A01K67/027 ; A01K67/00
Abstract:
Disclosed are genetically modified human pancreatic progenitor cells having an exogenous nucleic acid molecule encoding TGIF2, for use as a medicament in the treatment of a subject with diabetes. In addition methods for the production of such cells are described. Also disclosed is an expression vector encoding TGIF2 for use as a medicament in the treatment of a subject with diabetes.
Public/Granted literature
- US20160017289A1 TGIF2-INDUCED REPROGRAMMING OF HEPATIC CELLS TO PANCREATIC PROGENITOR CELLS AND MEDICAL USES THEREOF Public/Granted day:2016-01-21
Information query
